Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 + HLX10 with or without carboplatin/nab-paclitaxel for first-line squamous NSCLC
CTR20213369Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Jan 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Pulmonary squamous cell carcinoma comparing HLX07 + HLX10 + carboplatin + nab-paclitaxel, HLX10 + carboplatin + nab-paclitaxel and HLX07 + HLX10 (3 arms). Primary endpoints: Objective response rate and Progression-free survival. Started Jan 2022; status: active.
02
Drugs
pimurutamabserplulimabcarboplatinpaclitaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20213369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213369.